BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400
613 results:

  • 1. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant prostate cancer.
    Turnham DJ; Mullen MS; Bullock NP; Gilroy KL; Richards AE; Patel R; Quintela M; Meniel VS; Seaton G; Kynaston H; Clarkson RWE; Phesse TJ; Nelson PS; Haffner MC; Staffurth JN; Pearson HB
    Cells; 2024 Apr; 13(8):. PubMed ID: 38667288
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genomic Correlates of prostate-Specific Membrane Antigen Expression and Response to
    Raychaudhuri R; Mo G; Tuchayi AM; Graham L; Gulati R; Pritchard CC; Haffner MC; Yezefski T; Hawley JE; Cheng HH; Yu EY; Grivas P; Montgomery RB; Nelson PS; Chen DL; Hope T; Iravani A; Schweizer MT
    JCO Precis Oncol; 2024 Apr; 8():e2300634. PubMed ID: 38662984
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
    Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
    Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.
    Cai H; Zhang B; Ahrenfeldt J; Joseph JV; Riedel M; Gao Z; Thomsen SK; Christensen DS; Bak RO; Hager H; Vendelbo MH; Gao X; Birkbak N; Thomsen MK
    Nat Commun; 2024 Mar; 15(1):2088. PubMed ID: 38453924
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. MYC induces CDK4/6 inhibitors resistance by promoting prb1 degradation.
    Ma J; Li L; Ma B; Liu T; Wang Z; Ye Q; Peng Y; Wang B; Chen Y; Xu S; Wang K; Dang F; Wang X; Zeng Z; Jian Y; Ren Z; Fan Y; Li X; Liu J; Gao Y; Wei W; Li L
    Nat Commun; 2024 Feb; 15(1):1871. PubMed ID: 38424044
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Molecular complexity of intraductal carcinoma of the prostate.
    Zhu S; Xu N; Zeng H
    Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Curcumin Enhances the Anti-cancer Efficacy of CDK4/6 Inhibitors in prostate cancer.
    Zhao H; Ding R; Han J
    Arch Esp Urol; 2024 Jan; 77(1):57-66. PubMed ID: 38374014
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Genetic and epigenetic features of neuroendocrine prostate cancer and their emerging applications.
    Zhang X; Barnett E; Smith J; Wilkinson E; Subramaniam RM; Zarrabi A; Rodger EJ; Chatterjee A
    Int Rev Cell Mol Biol; 2024; 383():41-66. PubMed ID: 38359970
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
    van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
    Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
    Gopalan A
    Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
    Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
    Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Association between copy number alterations estimated using low-pass whole genome sequencing of formalin-fixed paraffin-embedded prostate tumor tissue and cancer-specific clinical parameters.
    Salachan PV; Ulhøi BP; Borre M; Sørensen KD
    Sci Rep; 2023 Dec; 13(1):22445. PubMed ID: 38105358
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Integrative analysis of transcriptomic and metabolomic profiles reveals enhanced arginine metabolism in androgen-independent prostate cancer cells.
    Dai X; Shi X; Luo M; Li P; Gao Y
    BMC Cancer; 2023 Dec; 23(1):1241. PubMed ID: 38104097
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Targeting DNA methylation and B7-H3 in rb1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Drastic Synergy of Lovastatin and
    Yao CJ; Chang CL; Hu MH; Liao CH; Lai GM; Chiou TJ; Ho HL; Kuo HC; Yang YY; Whang-Peng J; Chuang SE
    Nutrients; 2023 Oct; 15(21):. PubMed ID: 37960146
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Targeting CBX3 with a Dual BET/PLK1 Inhibitor Enhances the Antitumor Efficacy of CDK4/6 Inhibitors in prostate cancer.
    Liang H; Yang C; Zeng R; Song Y; Wang J; Xiong W; Yan B; Jin X
    Adv Sci (Weinh); 2023 Dec; 10(36):e2302368. PubMed ID: 37949681
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Genomic characterization of IDH-mutant astrocytoma progression to grade 4 in the treatment setting.
    Rautajoki KJ; Jaatinen S; Hartewig A; Tiihonen AM; Annala M; Salonen I; Valkonen M; Simola V; Vuorinen EM; Kivinen A; Rauhala MJ; Nurminen R; Maass KK; Lahtela SL; Jukkola A; Yli-Harja O; Helén P; Pajtler KW; Ruusuvuori P; Haapasalo J; Zhang W; Haapasalo H; Nykter M
    Acta Neuropathol Commun; 2023 Nov; 11(1):176. PubMed ID: 37932833
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant prostate cancer.
    Wang R; Xu Q; Guo H; Yang G; Zhang J; Wang H; Xu T; Guo C; Yuan J; He Y; Zhang X; Fu H; Xu G; Zhao B; Xie J; Zhao T; Huang L; Zhang J; Peng B; Yao X; Yang B
    Cancer Res Commun; 2023 Nov; 3(11):2221-2232. PubMed ID: 37877742
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Miller KA; Degan S; Wang Y; Cohen J; Ku SY; Goodrich DW; Gelman IH
    Oncogene; 2024 Jan; 43(1):22-34. PubMed ID: 37875657
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Ultrasound targeted microbubble destruction using docetaxel and Rose Bengal loaded Microbubbles for targeted Chemo-Sonodynamic therapy treatment of prostate cancer.
    McKaig T; Logan K; Nesbitt H; Callan B; McKeown S; O'Sullivan JM; Kelly P; O'Rourke D; McHale AP; Callan JF
    Eur J Pharm Biopharm; 2023 Nov; 192():196-205. PubMed ID: 37858804
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 31.